GeneDx specializes in advanced genomic technologies, focusing on exome and genome sequencing to enhance diagnostic accuracy and speed for pediatric patients. Their tests are designed to deliver clinically actionable results, significantly improving the diagnostic yield compared to traditional methods like chromosomal microarray and multigene panels. With a commitment to patient care, GeneDx aims to make exome and genome sequencing the standard of care, particularly for conditions such as epilepsy, developmental disorders, and genetic disorders in newborns. Their innovative approach is supported by extensive clinical expertise and a robust internal database, which includes over 1.5 million unique samples and more than 700,000 clinical exomes and genomes sequenced.

The company has made significant strides in the field of genomics, identifying over 400 new disease-gene relationships and developing advanced tools for genomic data analysis. This dedication to research and development allows GeneDx to provide clear and actionable insights, reducing the number of variants of uncertain significance in their results. By leveraging their comprehensive testing capabilities and unmatched genomic data, GeneDx is positioned as a leader in the industry, committed to improving patient outcomes and accelerating the diagnostic process for a wide range of genetic conditions.

United States

At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test.

GeneDx

Company Details